Teronen O, Konttinen Y T, Lindqvist C, Salo T, Ingman T, Lauhio A, Ding Y, Santavirta S, Sorsa T
Department of Oral and Maxillofacial Surgery, University of Helsinki, Finland.
J Dent Res. 1997 Sep;76(9):1529-37. doi: 10.1177/00220345970760090401.
The exact molecular mechanisms of the loosening of a dental implant are not well-known. The characteristics of implant sulci are similar to those of periodontal sulci regarding gingival crevicular fluid (GCF) and peri-implant sulcular fluid (PISF). Proteolytic enzymes, matrix metalloproteinases (MMPs), participate in peri-implant tissue remodeling. Clodronate is a well-tolerated bisphosphonate-group drug currently used in bone-resorption-related diseases in humans. The mechanisms of bisphosphonate action are not clarified. Collagenase activity in diseased PISF was significantly higher than in the clinically healthy group. Immunoblotting disclosed that diseased PISF contained increased immunoreactives MMP-8 compared with the healthy PISF. The residual latent collagenase activity in the diseased PISF was activated by gold thioglucose and inhibited completely by 100 microM of doxycycline closely resembling pure neutrophil collagenase (MMP-8). The presence of MMP-8 in diseased but not in clinically healthy PISF may prove to be a useful biochemical indicator to monitor peri-implant health and disease. Pure human neutrophil collagenase (MMP-8) and the MMP-8 present in PISF and in the GCF of both loosening implants and periodontitis-affected teeth were efficiently inhibited in vitro by clodronate (50% inhibition [IC50] was achieved by 150 microM of clodronate), an osteoactive, antiresorptive bisphosphonate. Furthermore, the new finding suggests an extended and hitherto-undescribed potential for clodronate in preventing the loosening of both implants and teeth, based on a dual beneficial effect: prevention of both bone resorption/osteolysis and of soft tissue/dental ligament destruction. Potential new therapeutic indications based on the collagenase-inhibiting effect of clodronate provide potential new therapeutic indications for a variety of diseased involving connective tissue breakdown, such as periodontal disease, arthritides, and tumor invasion.
牙种植体松动的确切分子机制尚不清楚。在龈沟液(GCF)和种植体周龈沟液(PISF)方面,种植体龈沟的特征与牙周龈沟相似。蛋白水解酶,即基质金属蛋白酶(MMPs),参与种植体周组织重塑。氯膦酸盐是一种耐受性良好的双膦酸盐类药物,目前用于治疗人类与骨吸收相关的疾病。双膦酸盐的作用机制尚不清楚。患病PISF中的胶原酶活性显著高于临床健康组。免疫印迹显示,与健康PISF相比,患病PISF中免疫反应性MMP - 8增加。患病PISF中残留的潜在胶原酶活性被硫代葡萄糖金激活,并被100微摩尔强力霉素完全抑制,强力霉素与纯中性粒细胞胶原酶(MMP - 8)非常相似。患病但非临床健康的PISF中存在MMP - 8,这可能被证明是监测种植体周健康和疾病的有用生化指标。氯膦酸盐(一种具有骨活性的抗吸收双膦酸盐)在体外能有效抑制纯人中性粒细胞胶原酶(MMP - 8)以及存在于松动种植体和牙周炎患牙的PISF和GCF中的MMP - 8(150微摩尔氯膦酸盐可实现50%抑制[IC50])。此外,这一新发现表明氯膦酸盐在预防种植体和牙齿松动方面具有扩展的、迄今未被描述的潜力,基于双重有益作用:预防骨吸收/骨溶解以及软组织/牙周韧带破坏。基于氯膦酸盐的胶原酶抑制作用的潜在新治疗适应症为多种涉及结缔组织破坏的疾病提供了潜在的新治疗适应症,如牙周病、关节炎和肿瘤侵袭。